ReviewAtherosclerosis2019
Long intergenic noncoding RNAs in cardiovascular diseases: Challenges and strategies for physiological studies and translation.
Review in Atherosclerosis, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Lnc-CHRM4-2:1 Inhibits M2 Polarization and Efferocytosis of Macrophages by Downregulating MerTK and SLC2A1 in Rheumatoid Arthritis.Journal of immunology research · 2026Article
- LncRNA SNHG15 promotes angiogenesis and improves cardiac repair after myocardial infarction through MiR-665-mediated KDR expression.Cellular and molecular life sciences : CMLS · 2025Article
- miRNA-133 and lncRNA-H19 expressions and their relation to serum levels of PKM2 and TGF-β in patients with systemic sclerosis.Non-coding RNA research · 2024Article
- Human lncRNAInternational journal of molecular sciences · 2023Article
- Review
- MALAT1 promotes platelet activity and thrombus formation through PI3k/Akt/GSK-3β signalling pathway.Stroke and vascular neurology · 2023Article
- Human Macrophage Long Intergenic Noncoding RNA,Arteriosclerosis, thrombosis, and vascular biology · 2023Article
- Enhanced myogenesis through lncFAM-mediated recruitment of HNRNPL to the MYBPC2 promoter.Nucleic acids research · 2022Article
- MALAT1 regulates hypertrophy of cardiomyocytes by modulating the miR-181a/HMGB2 pathway.European journal of histochemistry : EJH · 2022Article
- Determination of Optimum Ratio of Cationic Polymers and Small Interfering RNA with Agarose Gel Retardation Assay.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Suppression of lncRNA NLRP3 inhibits NLRP3-triggered inflammatory responses in early acute lung injury.Cell death & disease · 2021Article
- Long Non-Coding RNA Regulation of Epigenetics in Vascular Cells.Non-coding RNA · 2021Review
- Targeting Human lncRNAs for Treating Cardiometabolic Diseases.Cardiovascular drugs and therapy · 2021Article
- Long noncoding RNAs-a new dimension in the molecular architecture of the bile acid/FXR pathway.Molecular and cellular endocrinology · 2021Review
- Epigenetic Mechanisms in Diabetic Vascular Complications and Metabolic Memory: The 2020 Edwin Bierman Award Lecture.Diabetes · 2021Article
- Nonconserved Long Intergenic Noncoding RNAs Associate With Complex Cardiometabolic Disease Traits.Arteriosclerosis, thrombosis, and vascular biology · 2021Article
- LncRNA TUG1 regulates ApoM to promote atherosclerosis progression through miR-92a/FXR1 axis.Journal of cellular and molecular medicine · 2020Article
- LncRNAs and circular RNAs as endothelial cell messengers in hypertension: mechanism insights and therapeutic potential.Molecular biology reports · 2020Review
- Systematic analysis of long non-coding RNA and mRNA expression changes in ApoE-deficient mice during atherosclerosis.Molecular and cellular biochemistry · 2019Article
- ncRNA2MetS: a manually curated database for non-coding RNAs associated with metabolic syndrome.PeerJ · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Long intergenic noncoding RNAs (lincRNAs) are increasingly recognized as important mediators of many biological processes relevant to human pathophysiologies, including cardiovascular diseases. In vitro studies have provided important knowledge of cellular functions and mechanisms for an increasing number of lincRNAs. Dysregulated lncRNAs have been associated with cell fate programming and development, vascular diseases, atherosclerosis, dyslipidemia and metabolic syndrome, and cardiac pathological hypertrophy. However, functional interrogation of individual lincRNAs in physiological and disease states is largely limited. The complex nature of lincRNA actions and poor species conservation of human lincRNAs pose substantial challenges to physiological studies in animal model systems and in clinical translation. This review summarizes recent findings of specific lincRNA physiological studies, including MALAT1, MeXis, Lnc-DC and others, in the context of cardiovascular diseases, examines complex mechanisms of lincRNA actions, reviews in vivo research strategies to delineate lincRNA functions and highlights challenges and approaches for physiological studies of primate-specific lincRNAs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.